Ovid Therapeutics Inc is reported as having 7,029,223 shares beneficially owned by Balyasny-affiliated reporting persons, representing 5.33% of the company's common stock based on 131,874,634 shares outstanding as of March 16, 2026. The filing states the holdings are held through investment vehicles (ADMF and APHC) and notes 1,496,150 shares issuable upon exercise of warrants and exercise blockers termed the "Beneficial Ownership Limitation" and the "Second Beneficial Ownership Limitation".
Positive
None.
Negative
None.
Insights
Balyasny group reports a 5.33% beneficial stake in Ovid through managed funds.
The filing lists 7,029,223 shares as the voting and dispositive power held or controlled by BAM, BAM GP, BAM Holdings, Dames, and Dmitry Balyasny, tied to ADMF and APHC positions. The percentage is calculated from 131,874,634 shares outstanding as of March 16, 2026.
The disclosure also details warrant-related issuable shares and explicit blockers: the Beneficial Ownership Limitation (4.99%) and the Second Beneficial Ownership Limitation (9.99%). Future trading or dilution depends on holder exercises and these exercise blockers; subsequent filings would show any changes.
The statement clarifies multi-entity control and fund ownership rather than individual direct ownership.
The report attributes voting and investment power to a chain of entities (BAM → BAM GP → BAM Holdings → Dames → Dmitry Balyasny) and identifies ADMF and APHC as the direct holders of the reported shares. It states ADMF and APHC have rights to dividends or sale proceeds.
Significant compliance details include the exercise blockers on warrants; these are verbatim limits that affect how many shares may be acquired via warrant exercise. Monitoring future ownership amendments will show any exercise or voting changes.
Key Figures
Beneficially owned shares:7,029,223 sharesPercent of class:5.33%Shares outstanding:131,874,634 shares+4 more
7 metrics
Beneficially owned shares7,029,223 sharesvoting and dispositive power reported by Balyasny entities
Percent of class5.33%based on 131,874,634 shares outstanding as of March 16, 2026
Shares outstanding131,874,634 sharesas of <date>March 16, 2026</date>
ADMF direct holdings771,407 sharesdirect holder reported in filing
APHC direct holdings6,257,816 sharesdirect holder reported (includes issuable shares)
Shares issuable upon warrants1,496,150 sharesreferenced as issuable upon exercise of warrants
Series B Warrants1,428,500 warrantsSeries B Warrants noted in filing subject to blocker
Key Terms
Beneficial Ownership Limitation, Prefunded Warrants, Series B Warrants, Beneficially owned
4 terms
Beneficial Ownership Limitationregulatory
"prevents the holder from exercising the Warrants to the extent that, upon such exercise, the holder would beneficially own in excess of 4.99%"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
Prefunded Warrantsfinancial
"1,496,150 Prefunded Warrants subject to a Second Beneficial Ownership Limitation"
Prefunded warrants are a security that gives the holder the right to convert the warrant into a share after paying a very small remaining amount because almost the full purchase price was paid upfront. They matter to investors because exercising them increases the company’s outstanding shares (dilution) and can provide immediate cash to the issuer while allowing holders to bypass ownership limits or simplify timing, similar to buying a nearly-complete gift card that only needs a tiny top-up to use.
Series B Warrantsfinancial
"1,428,500 Series B Warrants subject to the Beneficial Ownership Limitation"
Series B warrants are contracts issued alongside a company's Series B financing that give the holder the right to buy a set number of shares at a fixed price within a specified time. For investors, they matter because they can provide leveraged upside if the company grows, or they can dilute existing shareholders when exercised—like a coupon promising a future share at a known price that can add value or change ownership stakes.
Beneficially ownedregulatory
"each of the Reporting Persons may be deemed to be the beneficial owner of approximately 5.33% of the Shares"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Ovid Therapeutics Inc
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
690469101
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
690469101
1
Names of Reporting Persons
Balyasny Asset Management L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
7,029,223.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
7,029,223.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
7,029,223.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.33 %
12
Type of Reporting Person (See Instructions)
IA, PN
SCHEDULE 13G
CUSIP Number(s):
690469101
1
Names of Reporting Persons
BAM GP LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
7,029,223.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
7,029,223.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
7,029,223.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.33 %
12
Type of Reporting Person (See Instructions)
HC, OO
SCHEDULE 13G
CUSIP Number(s):
690469101
1
Names of Reporting Persons
Balyasny Asset Management Holdings LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
7,029,223.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
7,029,223.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
7,029,223.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.33 %
12
Type of Reporting Person (See Instructions)
HC, PN
SCHEDULE 13G
CUSIP Number(s):
690469101
1
Names of Reporting Persons
Dames GP LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
7,029,223.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
7,029,223.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
7,029,223.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.33 %
12
Type of Reporting Person (See Instructions)
HC, OO
SCHEDULE 13G
CUSIP Number(s):
690469101
1
Names of Reporting Persons
Dmitry Balyasny
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
7,029,223.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
7,029,223.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
7,029,223.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.33 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Ovid Therapeutics Inc
(b)
Address of issuer's principal executive offices:
441 Ninth Avenue, 14th Floor, New York, NY 10001
Item 2.
(a)
Name of person filing:
This statement is being filed by (1) Balyasny Asset Management L.P., a Delaware limited partnership ("BAM"), (2) BAM GP LLC, a Delaware limited liability company ("BAM GP"), (3) Balyasny Asset Management Holdings LP, a Delaware limited partnership ("BAM Holdings"), (4) Dames GP LLC, a Delaware limited liability company ("Dames"), and (5) Dmitry Balyasny, a United States citizen (collectively, the "Reporting Persons"). BAM GP is the General Partner of BAM. BAM Holdings is the Sole Member of BAM GP. Dames is the General Partner of BAM Holdings. Dmitry Balyasny is the Managing Member of Dames.
(b)
Address or principal business office or, if none, residence:
The principal business address of each of BAM, BAM GP, BAM Holdings, Dames, and Mr. Balyasny is located at 444 West Lake Street, 50th Floor, Chicago, IL 60606.
(c)
Citizenship:
(1) BAM is a Delaware limited partnership, (2) BAM GP is a Delaware limited liability company, (3) BAM Holdings is a Delaware limited partnership, (4) Dames is a Delaware limited liability company, and (5) Mr. Balyasny is a United States citizen.
(d)
Title of class of securities:
Common Stock, par value $0.001 per share
(e)
CUSIP Number(s):
690469101
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
By virtue of its position as the investment manager of Atlas Diversified Master Fund, Ltd. ("ADMF"), the direct holder of the 771,407 shares of common stock, par value $0.001 per share ("Shares"), reported herein, and by virtue of its position a sthe invetsment manager of Atlas Private Holdings (Cayman) Ltd ("APHC"), the direct holder of 6,257,816 Shares (including 1,496,150 shares issuable from the exercise of warrants), BAM may be deemed to exercise voting and investment power over such Shares held by ADMF and APHC and thus may be deemed to beneficially own such Shares. By virtue of its position as the General Partner of BAM, BAM GP may be deemed to exercise voting and investment power over the Shares held directly by ADMF and APHC and thus may be deemed to beneficially own such Shares. By virtue of its position as the Sole Member of BAM GP, BAM Holdings may be deemed to exercise voting and investment power over the Shares held directly by ADMF and APHC and thus may be deemed to beneficially own such Shares. By virtue of its position as the General Partner of BAM Holdings, Dames may be deemed to exercise voting and investment power over the Shares held directly by ADMF and APHC and thus may be deemed to beneficially own such Shares. By virtue of his position as the Managing Member of Dames, Mr. Balyasny may be deemed to exercise voting and investment power over the Shares held directly by ADMF and APHC and thus may be deemed to beneficially own such Shares.
(b)
Percent of class:
Each of the Reporting Persons may be deemed to be the beneficial owner of approximately 5.33% of the Shares, based on 131,874,634 Shares outstanding as of March 16, 2026, as reported in the Issuer's annual report on form 10-K filed with the Securities and Exchange Commission on March 18, 2026. The report amount consists of 5,533,073 shares and 1,496,150 shares issuable upon the exercise of 1,428,500 Series B Warrants subject to the Beneficial Ownership Limitation (as defined herein) and 1,496,150 Prefunded Warrants subject to a Second Beneficial Ownership Limitation (as defined herein). The Series B Warrants are subject to a blocker which prevents the holder from exercising the Warrants to the extent that, upon such exercise, the holder would beneficially own in excess of 4.99% of the Shares outstanding as a result of the exercise (the "Beneficial Ownership Limitation") and the Prefunded Warrants are subject to a blocker which prevents the holder from exercising the Warrants to the extent that, upon such exercise, the holder would beneficially own in excess of 9.99% of the Shares outstanding as a result of the exercise (the "Second Beneficial Ownership Limitation").
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Each of the Reporting Persons has the sole power to vote or to direct the vote of 7,029,223 shares.
(ii) Shared power to vote or to direct the vote:
0
(iii) Sole power to dispose or to direct the disposition of:
Each of the Reporting Persons has the sole power to vote or to direct the vote of 7,029,223 shares.
(iv) Shared power to dispose or to direct the disposition of:
0
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
ADMF and APHC, are both Cayman Islands exempted companies that are investment management clients of BAM, have the right to receive dividends from, or the proceeds from the sale of, the reported securities.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
The filing states 7,029,223 shares beneficially owned, equal to 5.33% of common stock based on 131,874,634 shares outstanding as of March 16, 2026.
Through which entities does Balyasny hold OVID shares?
Holdings are reported through investment vehicles: Atlas Diversified Master Fund (ADMF) and Atlas Private Holdings (APHC), with BAM and related entities exercising voting/investment power.
Are there warrant-related shares mentioned in the filing?
Yes; the filing references 1,496,150 shares issuable upon exercise of warrants and describes Series B Warrants and Prefunded Warrants subject to ownership blockers.
What are the ownership limits described in the filing?
The filing cites a Beneficial Ownership Limitation preventing exercise above 4.99% and a Second Beneficial Ownership Limitation preventing exercise above 9.99% of outstanding shares.
Who signed the Schedule 13G for these reporting persons?
The filing is signed by Scott Schroeder as Authorized Signatory for the entities and by Dmitry Balyasny personally, dated 05/11/2026.
